throbber

`
`Hairless Mouse Skin is Limited as a Model for Assessing
`the Effects of Penetration Enhancers in Human Skin
`
`John Russell Bond, Ph.D., and Brian William Barry, Ph.D., D.Sc.
`Postgraduate School of Studies in Pharmacy, University of Bradford, Bradford, U.K.
`
`
`was no consistent relationship between enhancer effects on
`through
`The permeability coefficient of 5-fluorouracil
`human abdominal and hairless mouse skins was used as an
`the two skin types, and we concludethat the hairless mouse
`model should notbeused to predictthe effects ofpenetration
`indicator of the relative effects of 12-h pretreatment ofthe
`enhancers in humanskin. After treatment withsaline, hatr-
`skins with either penetration-enhancer mixtures[including
`less mouse skin sharply increased in permeability after ap-
`laurocapram (Azone), decylmethylsulfoxide, oleic acid, and
`proximately 50 h hydration, suggesting that the stratum cor-
`propylene glycol] or saline (control). After treatment with
`neumhadstarted to disrupt, whereas the flux through human
`saline, fluxes of 5-fluorouracil through the two skin types
`skin remained unchanged. J Invest Dermatol 90:810-813,
`were similar, but the mouse skin showed exaggerated re-
`1988
`sponsesto all the penetration-enhancer formulations. There
`
`he range of drugsthat can beeffectively delivered via
`the percutaneous route is limited largely by the rela-
`tive impermeability of the stratum corneum. Various
`methods ofincreasing the absorption of poorly pene-
`trating agents have been attempted, withearlier stud-
`ies concentrating often onthe effects of occlusion and hydration and
`morerecentinvestigations dwelling on penetration enhancers [1,2].
`Such accelerants reduce the barrier properties of the stratum cor-
`neum to other permeants, thereby potentially increasing the range
`of drugs that can be delivered through the skin.
`The developmentoftopical formulations containing penetration
`enhancers often involvesin vitro work withisolated skin. As human
`tissue is not always readily available, various animal models have
`beenused, with hairless mouse skin currently being popular.
`In this paper, we comparetheeffects ofpretreatmentwith a range
`of penetration enhancers on the permeabilities of human abdominal
`and hairless mouse skins to a model permeant, 5-fluorouracil
`(5-FU). We conclude that hairless mouse skin is a poor mimic of
`human skin with respect to enhanceractivity.
`MATERIALS AND METHODS
`
`We used the pseudo-steady-state permeability coefficient (K,) of
`5-FU as a test for the relative effects of 12-h pretreatments with
`sevenpotential penetration-enhancer formulations compared with
`normal saline (control). Previous work [3] has shown that such
`pretreatment optimizes penetration-enhancement effects. Effects
`on human abdominaland hairless mouse skins were compared to
`assess the suitability of the hairless mouse as. a model for human skin
`as modified by penetration enhancers.
`
`Manuscript received July 15, 1987; accepted for publication December
`23, 1987.
`This work was supported by a grant from 3M Health Care, Lough-
`borough, England. Reprint requests to: B. W. Barry, Postgraduate School of
`Studies in Pharmacy, University of Bradford, West Yorkshire, BD7 1DP,
`U.K.
`Abbreviations:
`5-FU: 5-fluorouracil
`DCMS:decylmethylsulfoxide
`
`Skin Sources and Preparation. Four male hairless mice (CBA/
`HLstrain) aged 60 to 80 days werekilled by spinaldislocation,
`their dorsal skins were immediately excised, any underlying "ssU¢
`being gently removed. Each mouse supplied 12 skin samples for use
`in permeation experiments.
`b
`Human midline abdominal skin from caucasian donors was Cc
`tained at autopsy and stored in evacuated polythenebags at —20°C
`until required [4]. Samples were sectioned with a dermatome (Davis
`Duplex 7) to approximately 420-~um-thick sections consisting ©
`the epidermis and a portion ofthe dermis. Two pieces of human
`abdominalskin were used (males, 60 and 63 years), each providing
`24 samples (3 from each donorfor each of the 8 pretreatments).
`The numberofreplicates allowed for occasionalcell leakage with
`consequentrejection of data, a common problem within vitro skin
`permeation work.
`Pretreatment Formulations. Three potentially useful penetra-
`tion enhancers ofdifferent chemical types —laurocapram (Azone,
`donated by Nelson Research), decylmethylsulfoxide (DCMS, do-
`nated by Procter and Gamble Co.), and oleic acid (Sigma Chemical
`Co., minimumassay 99%) — were tested. Oleic acid was used as a
`solution in propylene glycol, and laurocapram and DCMS were
`applied in both water and propyleneglycol. Concentrationsofpen-
`etration enhancers were chosen from published data,
`including
`work from this department[5]. Laurocapram 2% in propylenegly-
`col, oleic acid 5% in propylene glycol, and DCMS 15% in propy!-
`ene glycol were used by Barry and Bennett [6]. DCMS 4% in water
`was used by Sekura and Scala [7], and laurocapram 3% in 0.1%
`polysorbate 20/normalsaline has also been demonstratedas effec-
`tive [3,8]. As the mainaimofthe work was to comparetheeffects of
`a variety of enhancers on two skin types, different concentrations
`were deliberately chosen. A solution of 0.1% polysorbate 20
`(Tween 20)in normalsaline wasincluded as a control for the emul-
`sion of laurocapramin saline. Propylene glycol was included as a
`controlfor the enhancersolution based onthis solvent andtotest for
`enhancementeffects of the solventitself (see Table I).
`
`Automatic Diffusion Apparatus. Skin samples were mounted
`into stainless-steel diffusion cells (cross-sectional area 0.126 cm’)
`maintained at 31+ 1°C on hollow copper arms through which
`thermostated water was pumped. Receptorfluid (0.002% aqueous
`
`0022-202X/88/$03.50 Copyright © 1988 by The Society for Investigative Dermatology,Inc.
`810
`
`0001
`
`Noven Pharmaceuticals, Inc.
`EX2019
`Mylan Tech., Inc. v. Noven Pharma., Inc.
`IPR2018-01119
`
`

`

`VOL. 90, NO. 6 JUNE 1988
`
`PENETRATION ENHANCERS IN HUMAN AND MOUSESKINS 811
`
`6
`
`‘ome
`
`A
`
`12
`
`08
`
`€Oo
`
`a £
`
`04
`
`2
`oeCy
`.
`g 12 ao6

`B
`
`i 6£o
`
`s=
`&
`8
`al
`E=
`
`3 40
`
`ere
`

`
`60
`
`20
`Time (h)
`
`Pretreatment of Skin Samples and Permeation Studies.
`Each treatment mixture was applied to six samples of both skin
`types, consisting of 150 uL of water-based mixtures (= 1200
`pL cm) and 10 wL of propylene glycol-based mixtures (= 80
`iL cm7). Liquids remained on the skin for 12 h; then they were
`gently removed with absorbent tissue and permeation studies com-
`menced immediately.
`The donorsolutions consisted of 160 uL of a radiolabeled satu-
`rated (10.2 mg cm73)solution of 5-FU indistilled water [5-fluoro-
`6-[>H]uracil
`(Amersham International PLC) was diluted to
`0.3 mCi cm74]. Receptor samples werecollected over 2 h intervals,
`up to 60 h, and assayed for 5-FU contentby liquid scintillation
`counting (Packard Tri-Carb 460C) after the addition of 10 cm? of
`Scintran Cocktail T (BDH Chemicals Ltd.).
`Calculation of Permeability Coefficients. Raw data from
`scintillation counting were converted to cumulative amounts per
`unit area (mg cm~?) and computer-plotted versus time; for exam-
`ples, see Fig 1. Steady-state penetration fluxes, J (mg cm~? h7),
`were calculated by regression analysis from the linear regions of the
`plots (r typically equaled 0.998). Pretreatment with aqueous
`DCMS, however, consistently produced an atypical penetration
`plot, witha rapidinitial absorption followedbya fall in rate; fluxes
`were calculated from theinitial slope after this pretreatment(r typi-
`cally 0.98). Permeability coefficients, K, (cm h~'), were calculated
`from the steady-state flux and donor concentration, C (mg cm™~),
`using the relationship
`
`K,=J/C
`
`RESULTS
`
`Table 1 shows the mean permeability coefficients (K,) calculated
`for 5-FU, for both skin types, after each treatment. From these
`values, we calculated enhancementratios for each enhancertreat-
`ment, and bothskin types, from the formula
`.
`K,, of 5-FU after enhancer treatment
`enhancement ratio = ———________—_____
`K,of 5-FUafter saline treatment
`Theratios calculated for each treatment and skin type are com-
`pared in Fig 2.
`The cumulative 5-FU penetration plots for saline-pretreated
`hairless mouse skin differed markedly from those obtained with
`humanabdominalskin (Fig 3). Fluxes through hairless mouse skin
`increased dramatically after 35 to 40 h permeation, corresponding
`to 47 to 52 h hydration.
`
`Figure 1. Sample penetration plots for 5-FU through human abdominal
`skin after pretreatmentof the skin with oneofthe test mixtures. A. Polysor-
`bate 20 in saline (inverted opentriangles), propylene glycol (closed triangles),
`laurocapram in polysorbate 20/saline (opencircles) and laurocapram in pro-
`pylene glycol(closed circles). B. Normalsaline (opentriangles), aqueous decyl-
`methylsulfoxide (open diamonds), decylmethylsulfoxide in propylene glycol
`(closed diamonds) and oleic acid in propylene glycol (closed squares).
`
`sodium azide) flowed continuously through the receptor chamber
`and was collected in glass scintillation vials. Flow rate was
`2 cm? h~', corresponding to 40 changes of receptor volume per
`hour,ensuring sink conditions. The vials were changed automati-
`cally at 2-h intervals; a detailed description of the diffusion system
`has been published by Akhteretal (oi.
`
`Table I, Formulas and Volumesof the Eight Pretreatments Applied to the Skin Samples and Resultant Permeability Coefficients (K,)
`of 5-Fluorouracil Through Human Abdominal and Hairless Mouse Skins
`
`Pretreatment Formula
`
`Normalsaline (0.9% sodium chloride)
`
`Human Abdomen Hairless Mouse
`
`Mean K,!
`SEM‘
`nd
`Mean K,
`SEM
`n
`Code*
`
`Ss
`0.951
`0.451
`5
`1.07
`0.457
`6
`0.1% Polysorbate 20 in normalsaline
`TS
`1.03
`0.466
`5
`3.44
`0.610
`
`5
`
`3% w/v Laurocapram in 0.1% Polysorbate/saline
`
`4% w/v Decylmethylsulfoxide in water
`
`Propylene glycol
`2% w/v Laurocapram in propylene glycol
`
`15% w/v Decylmethylsulfoxide in propylene glycol
`
`LTS
`
`DCAQ
`
`PG
`LPG
`
`DCPG
`
`6.48
`
`71.3
`
`2.53
`17.7
`
`2.15
`
`1.14
`
`23.9
`
`0.785
`5ole
`
`0.688
`
`6
`
`6
`
`6
`6
`
`4
`
`11.4
`
`107
`
`4.88
`142
`
`6.59
`
`1.04
`
`8.18
`
`1.21
`36.2
`
`0.938
`
`6
`
`6
`
`5
`6
`
`6
`
`5% w/v Oleic acid in propylene glycol
`
`OAPG
`
`19.3
`
`6.20
`
`o
`
`159
`
`15.5
`
`6
`
`
`bPermesltycocficent()%10am
`€ Standard error of the mean.
`Numberofreplicates.
`
`0002
`
`

`

`812 BOND AND BARRY
`
`THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
`
`150 100
`
`
`
`Enhancementratio
`
`sion of laurocapram(@ < 0.005), increasing to 18-fold when a solu-
`tion in propylene glycol was used (a@ <0.0005). Propylene glycol
`alone had a moderate enhancingeffect, increasing permeability to
`5-FU some 2.6 times (@ <0.025). The polysorbate 20 used to
`emulsify laurocapramin water insignificantly changed humanskin
`permeability to 5-FU (@ > 0.05), in agreement with previous work
`that showed that nonionics are the least damaging class of surfac-
`tants (e.g., [12,13]).
`DCMSin aqueous solution initially produced a high flux of
`5-FU,the effect being reversible as the DCMS was washed out of
`the skin [14]. DCMSinpropyleneglycol, in contrast, exerted very
`little effect on skin permeability, slightly less than that ofpropylene
`glycol alone. The effect of DCMS may have been reduced here
`because propylene glycol was a good solvent for the enhancer and
`inhibited its partitioning into the stratum corneum.
`Oleic acid is an effective penetration enhancer for lipophilic
`compounds, whenusedasa solution in propylene glycol [15]. We
`have foundit to beas effective as laurocapramin promoting perme-
`ation of 5-FU (a polar drug) when applied in this way.
`Comparison of Hairless Mouse and Human Skins. Theper-
`meability coefhcients for 5-FU through human abdominal and
`hairless mouse skins pretreated withsaline weresimilar, suggesting
`that the mouse model may have somevalidity in simple,idealsitua-
`tions; however, after penetration-enhancer pretreatment,the hair-
`less mouse model was misleading. Application of aqueouspolysor-
`bate 20, which had nosignificant effect on human abdominal skin
`(a > 0.05), increased the permeability of hairless mouse skin 3-fold
`(a <0.01).
`Figure 1 demonstrates that all pretreatments modified hairless
`K,, of 5-FU after enhancer treatment
`;
`mouse skin more than they did human skin. Therelative effect of
`enhanceméiit- ratio =—————————_
`each enhancer formulation on the two skins was not consistent.
`K, of 5-FUaftersaline treatment
`Thus, laurocapram in propylene glycol was 7 times more active in
`promoting 5-FU penetration through hairless mouse skin than
`through human abdominal skin, whereas the corresponding ratio
`for the aqueous emulsionof laurocapram wasonly 1.6. As there was
`no consistent relationship between penetration-enhancement ef-
`fects on the two skin types, we conclude that hairless mouse skin
`cannotbe used as a reliable model for humanpercutaneous absorp-
`tion as modified by accelerant treatment. The enhancementratios
`found for the accelerants used here werecalculated withrespect to
`5-FU. It is likely that enhancementeffects will change according to
`the chemical nature of the permeantused |6,16], and this would add
`additionalvariability and therefore potential inaccuracy to use ofthe
`hairless mouse model.
`Previous work explains therise in permeability after 50 h hydra-
`tion of hairless mouse skin pretreated withsaline [17]. Prolonged
`hydration completely disrupts hairless mouse skin and therise in
`permeability seen in the present work probably coincided with the
`start of stratum corneum breakdown, which would allow rapid
`permeation of 5-FU through weakened regions of the horny layer.
`
`Figure 2. Enhancementratios for 5-FU through human abdominal skin
`(open bars) and hairless mouse skin (hatched bars) after 12-h pretreatment
`with the enhancer mixtures. Enhancement ratiosare calculated by the equa-
`tion.
`
`Codesare defined in Table I.
`
`DISCUSSION
`
`Effects of Penetration Enhancers on Human Skin. Statistical
`analysis was performedusing the Wilcoxon-Mann- Whitney rank
`sum eu , taking a levelofsignificance (a) of0.05.In testing for
`effects of
`the penetration enhancers (comparedwithsaline control)
`a one-tailed test was used, but in comparing human abdominal and
`hairless mouse skins we used a two-tailed test.
`All the effects ofpenetration enhancers shown by human abdom-
`inal skin agree with previous studies. Laurocapram waseffective
`whenused as an emulsion (e.g., [3,8]), but other workers found that
`its action was heightened by propyleneglycol[11]. We discovered a
`near 7-fold rise in skin permeability after treatment with the emul-
`
`06
`
`Cumulativeweightof5-FUpenetrated(mgcm?)
`
`o4
`
`Qo
`
`20
`
`Time(h)
`
`40
`
`60
`
`Figure 3, Comparison of 5-FU penetrationplots through human abdomi-
`nal
`(opentriangles) and hairless mouse (inverted closed triangles) skins afteQgg3
`saline pretreatment.
`
`REFERENCES
`
`1. Barry BW:Properties that influence percutaneous absorption,in Der-
`matological Formulations: Percutaneous Absorption. Marcel
`Dekker, New York, 1983, pp 127-233
`2. Woodford R, Barry BW: Penctration enhancers and the percutaneous
`absorption of drugs: An update, J Toxicol Cutaneous Ocular Toxi-
`col 5:165-175, 1986
`3. Sugibayashi K, Hosoya KI, Morimoto Y, Higuchi WI: Effect of the
`absorption enhancer, Azone, on the transport of 5-fluorouracil
`across hairless rat skin. ] Pharm Pharmacol 37:578- 580, 1985
`4. Harrison SM, Barry BW, Dugard PH: Effects of freezing on human
`skin permeability. J Pharm Pharmacol 36:261-262, 1984
`5, Goodman M,Barry BW:Action ofskin permeation enhancers Azone,
`oleic acid and decylmethy! sulphoxide: Permeation and DSC stud-
`ics. ] Pharm Pharmacol 38:71P, 1986
`Barry BW, Bennett SL: Effect ofpenetration enhancers on the pene
`ation ofmannitol, hydrocortisone andprogesterone through human
`skin. J Pharm Pharmacol 39:535 - 546, 1987
`
`6.
`
`

`

`VOL. 90, NO. 6 JUNE 1988
`
`PENETRATION ENHANCERS IN HUMAN AND MOUSE SKINS 813
`
`7.
`
`10.
`
`11.
`
`Sekura DL, Scala J: The percutaneousabsorption of alkyl methyl sul-
`foxides, in Advances in Biology of the Skin, vol 12. Edited by W
`Montagna, EJ Van Scott, RB Stoughton, Appleton-Century-
`Crofts, New York, 1972, pp 257-269
`Shannon WM, Westbrook L, Higuchi WI, Sugibayashi K, Baker DC,
`KumarSD,FoxJL, Flynn GL, Ho NFH,Vaidyanathan R:Influence
`of 1-dodecylazacycloheptan-2-one (Azone) on the topical therapy
`of cutancous herpes simplex virus type 1 infection in Taiietaes mice
`with 2’, 3‘-di-O-acetyl-9-f-p-arabinofuranosyladenine and 5’-O-
`valeryl-9-f-p-arabinofuranosyladenine. J Pharm Sci 74:1157-
`1161, 1985
`Akhter SA, Bennett SL, Waller IL, Barry BW: An automateddiffusion
`apparatus for studying skin penetration. Int J Pharm 21:17-26,
`1984
`
`Iman RL, Conover WJ: A Modern ApproachtoStatistics. John Wiley,
`New York, 1983, pp 280-287
`Wotton PK, Mollgaard B, Hadgraft J, Hoelgaard A: Vehicleeffect on
`topical drug delivery, III. Effect of Azone on the cutaneous perme-
`ation of metronidazole and propylene glycol. Int J Pharm 24:19-
`26, 1985
`
`12,
`
`13.
`
`14.
`
`ao;
`
`16.
`
`17.
`
`Lansdown ABG,Grasso P: Physico-chemicalfactors influencing epi-
`dermal damageby surface active agents. Br] Dermatol 86:361-373,
`1972
`Dalvi UG, Zatz JL: Effect of nonionic surfactants on penetration of
`dissolved benzocaine through hairless mouse skin. J] Soc Cosmet
`Chem32:87-94, 1981
`Cooper ER:Effects of decylmethylsulfoxide on skin penetration, in
`Solution BehaviourofSurfactants, Theoretical and Applied Aspects,
`vol 12. Edited by KL Mittel, EJ Fendler. Plenum Press, New York,
`1982, pp 1505-1516
`Cooper ER: Increased skin permeability for lipophilic molecules. J
`Pharm Sci 73:1153-1156, 1984
`Bennett SL, Barry BW: Effectiveness of skin penetration enhancers
`propylene glycol, Azone, decylmethylsulphoxide and oleic acid
`with modelpolar (mannitol) and nonpolar (hydrocortisone) pene-
`crants. J Pharm Pharmacol 37:84P, 1985
`Bond JR, Barry BW: Longtermhydration effects on permeability of
`hairless mouse skin. J Pharm Pharmacol 37:77P, 1985
`
`0004
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket